Docoh
Loading...

EVGN Evogene

Filed: 1 Jul 21, 7:00am


UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of July 2021
 
Commission File Number: 001-36187

EVOGENE LTD.
  (Translation of Registrant’s Name into English)
 
13 Gad Feinstein Street
Park Rehovot P.O.B 4173
Ness Ziona 7414003, Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F ☒       Form 40-F ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 

CONTENTS
 
Evogene Ltd., or the Company, reports changes in its management:
 
Mr. Lazer Bezdin has been appointed Chief Operating Officer, effective July 1, 2021.  Mr. Bezdin brings more than 20 years of business experience, mainly in the pharmaceuticals and clean-tech industries. His experience includes 10 years in various roles in Teva Pharmaceuticals Industries Ltd. (Nasdaq: TEVA). Immediately prior to joining the Company, he served as VP Sales & Business Development in Elcon Recycling, a subsidiary of Shikun & Binui Ltd. (TASE: SKBN).
 
In addition, Dr. Eyal Emmanuel has requested to reduce his management role as the Company’s Chief Scientific Officer, which he has held for over two years. Accordingly, effective July 1, 2021, Dr. Emmanuel will be appointed VP New Directions, on a part-time basis.
 
This Report of Foreign Private Issuer on Form 6-K is incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission, or SEC, File No. 333-253300), and Form S-8 (SEC File Nos. 333-193788, 333-201443 and 333-203856) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
 
2

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 



Date: July 1, 2021
 
EVOGENE  LTD.
(Registrant)

By: /s/ Dorit Kreiner
——————————————
Dorit Kreiner
Chief Financial Officer
 
3